251 related articles for article (PubMed ID: 34795033)
1. APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.
DiMarco AV; Qin X; McKinney BJ; Garcia NMG; Van Alsten SC; Mendes EA; Force J; Hanks BA; Troester MA; Owzar K; Xie J; Alvarez JV
Cancer Immunol Res; 2022 Jan; 10(1):70-86. PubMed ID: 34795033
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
Wang S; Jia M; He Z; Liu XS
Oncogene; 2018 Jul; 37(29):3924-3936. PubMed ID: 29695832
[TBL] [Abstract][Full Text] [Related]
3. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
Messerschmidt C; Obermayer B; Klinghammer K; Ochsenreither S; Treue D; Stenzinger A; Glimm H; Fröhling S; Kindler T; Brandts CH; Schulze-Osthoff K; Weichert W; Tinhofer I; Klauschen F; Keilholz U; Beule D; Rieke DT
Int J Cancer; 2020 Oct; 147(8):2293-2302. PubMed ID: 32468570
[TBL] [Abstract][Full Text] [Related]
4. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade.
Akhand SS; Liu Z; Purdy SC; Abdullah A; Lin H; Cresswell GM; Ratliff TL; Wendt M
Cancer Immunol Res; 2020 Dec; 8(12):1542-1553. PubMed ID: 33093218
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
Crosby EJ; Acharya CR; Haddad AF; Rabiola CA; Lei G; Wei JP; Yang XY; Wang T; Liu CX; Wagner KU; Muller WJ; Chodosh LA; Broadwater G; Hyslop T; Shepherd JH; Hollern DP; He X; Perou CM; Chai S; Ashby BK; Vincent BG; Snyder JC; Force J; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2020 Sep; 26(17):4670-4681. PubMed ID: 32732224
[TBL] [Abstract][Full Text] [Related]
8. Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer.
Zhang Y; Delahanty R; Guo X; Zheng W; Long J
Hum Genomics; 2015 Dec; 9():34. PubMed ID: 26682542
[TBL] [Abstract][Full Text] [Related]
9. Molecular origins of APOBEC-associated mutations in cancer.
Petljak M; Maciejowski J
DNA Repair (Amst); 2020 Oct; 94():102905. PubMed ID: 32818816
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like-Induced Protein Changes in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Throughout Disease Progression.
Bos MK; Smid M; Sleijfer S; Martens JWM
JCO Precis Oncol; 2022 Jan; 6():e2100190. PubMed ID: 35050709
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
Wang HQ; Mulford IJ; Sharp F; Liang J; Kurtulus S; Trabucco G; Quinn DS; Longmire TA; Patel N; Patil R; Shirley MD; Chen Y; Wang H; Ruddy DA; Fabre C; Williams JA; Hammerman PS; Mataraza J; Platzer B; Halilovic E
Cancer Res; 2021 Jun; 81(11):3079-3091. PubMed ID: 33504557
[TBL] [Abstract][Full Text] [Related]
12. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.
Roberts SA; Lawrence MS; Klimczak LJ; Grimm SA; Fargo D; Stojanov P; Kiezun A; Kryukov GV; Carter SL; Saksena G; Harris S; Shah RR; Resnick MA; Getz G; Gordenin DA
Nat Genet; 2013 Sep; 45(9):970-6. PubMed ID: 23852170
[TBL] [Abstract][Full Text] [Related]
13. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
[TBL] [Abstract][Full Text] [Related]
14. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
[TBL] [Abstract][Full Text] [Related]
15. APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential.
Butler K; Banday AR
J Hematol Oncol; 2023 Mar; 16(1):31. PubMed ID: 36978147
[TBL] [Abstract][Full Text] [Related]
16. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
17. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer.
Kanu N; Cerone MA; Goh G; Zalmas LP; Bartkova J; Dietzen M; McGranahan N; Rogers R; Law EK; Gromova I; Kschischo M; Walton MI; Rossanese OW; Bartek J; Harris RS; Venkatesan S; Swanton C
Genome Biol; 2016 Sep; 17(1):185. PubMed ID: 27634334
[TBL] [Abstract][Full Text] [Related]
18. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
20. Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis.
Petljak M; Alexandrov LB; Brammeld JS; Price S; Wedge DC; Grossmann S; Dawson KJ; Ju YS; Iorio F; Tubio JMC; Koh CC; Georgakopoulos-Soares I; Rodríguez-Martín B; Otlu B; O'Meara S; Butler AP; Menzies A; Bhosle SG; Raine K; Jones DR; Teague JW; Beal K; Latimer C; O'Neill L; Zamora J; Anderson E; Patel N; Maddison M; Ng BL; Graham J; Garnett MJ; McDermott U; Nik-Zainal S; Campbell PJ; Stratton MR
Cell; 2019 Mar; 176(6):1282-1294.e20. PubMed ID: 30849372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
